American Research & Management Has Boosted Gilead Sciences (GILD) Holding by $392,445 as Market Valuation Declined; Greylin Investment Mangement Has Trimmed Its Teva Pharmaceutical Inds LTD (TEVA) Position by $1.10 Million; Share Price Declined

February 23, 2018 - By Clifton Ray

American Research & Management increased its stake in Gilead Sciences Inc (GILD) by 32.9% based on its latest 2017Q3 regulatory filing with the SEC. American Research & Management bought 4,845 shares as the company’s stock declined 8.05% while stock markets rallied. The institutional investor held 19,570 shares of the health care company at the end of 2017Q3, valued at $1.59 million, up from 14,725 at the end of the previous reported quarter. American Research & Management who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $105.38B market cap company. The stock increased 1.60% or $1.27 during the last trading session, reaching $80.67. About 3.69 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 23, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Greylin Investment Mangement Inc decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 21.95% based on its latest 2017Q3 regulatory filing with the SEC. Greylin Investment Mangement Inc sold 64,630 shares as the company’s stock declined 15.11% while stock markets rallied. The institutional investor held 229,865 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $4.05 million, down from 294,495 at the end of the previous reported quarter. Greylin Investment Mangement Inc who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $20.33 billion market cap company. The stock increased 0.98% or $0.2 during the last trading session, reaching $20. About 5.53 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since February 23, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It is positive, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Clean Yield Group Inc owns 47,762 shares. Bender Robert And Assoc holds 4.47% or 96,042 shares. Lumina Fund Mngmt Limited Liability Company invested 0.06% in Gilead Sciences, Inc. (NASDAQ:GILD). Canada Pension Plan Board invested 0.63% in Gilead Sciences, Inc. (NASDAQ:GILD). Hamilton Point Invest Advsr Limited Liability Company invested in 1.01% or 23,071 shares. Prelude Capital Management Llc holds 0.07% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 9,366 shares. Adage Grp Llc invested in 0.32% or 1.63 million shares. Arete Wealth Advsr Lc reported 0.47% in Gilead Sciences, Inc. (NASDAQ:GILD). Limited Liability holds 0.18% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 32,099 shares. Parallax Volatility Advisers LP accumulated 69,737 shares. Nelson Roberts Inv Ltd Llc has invested 2.04% in Gilead Sciences, Inc. (NASDAQ:GILD). Ontario Teachers Pension Plan Board holds 0.08% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 74,733 shares. Hermes Invest Management invested 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD). Rhumbline Advisers invested in 2.32 million shares. Patten & Patten Tn accumulated 0.02% or 2,590 shares.

Since August 30, 2017, it had 0 buys, and 15 selling transactions for $56.94 million activity. $6.05 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by MARTIN JOHN C. On Tuesday, February 20 Alton Gregg H sold $1.18M worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 14,435 shares. Shares for $4.40 million were sold by Washington Robin L. Shares for $4.68 million were sold by WILSON GAYLE E on Friday, February 9.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 125 analyst reports since July 29, 2015 according to SRatingsIntel. Oppenheimer initiated Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, October 4 with “Hold” rating. The rating was maintained by Jefferies on Wednesday, October 5 with “Buy”. Jefferies maintained the stock with “Hold” rating in Tuesday, March 15 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, July 29 by Maxim Group. The firm has “Hold” rating given on Tuesday, October 3 by Needham. The company was maintained on Wednesday, October 4 by Bank of America. As per Monday, October 16, the company rating was maintained by Robert W. Baird. Oppenheimer initiated it with “Outperform” rating and $120 target in Thursday, February 11 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Market Perform” rating by Leerink Swann on Wednesday, February 7. Mizuho maintained it with “Buy” rating and $95.0 target in Monday, February 12 report.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 146 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, January 11 by Goldman Sachs. The rating was maintained by RBC Capital Markets on Wednesday, July 29 with “Outperform”. As per Monday, November 7, the company rating was downgraded by Bank of America. Morgan Stanley downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Monday, August 7 to “Underweight” rating. Credit Suisse upgraded the shares of TEVA in report on Monday, October 31 to “Outperform” rating. The company was downgraded on Monday, October 24 by Mizuho. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Neutral” rating given on Tuesday, September 29 by Nomura. As per Tuesday, December 12, the company rating was initiated by Guggenheim. Credit Suisse downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Friday, August 4 to “Neutral” rating. RBC Capital Markets maintained the stock with “Sell” rating in Wednesday, January 24 report.

Greylin Investment Mangement Inc, which manages about $435.83M and $436.72 million US Long portfolio, upped its stake in Helmerich & Payne Inc (NYSE:HP) by 50,130 shares to 99,995 shares, valued at $5.21M in 2017Q3, according to the filing. It also increased its holding in Nordic American Tankers Limi (NYSE:NAT) by 119,450 shares in the quarter, for a total of 517,525 shares, and has risen its stake in Greenhill & Co Inc (NYSE:GHL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: